Does myeloproliferative neoplasm (MPN) care have new developments? Dr. Kristen Pettit from Rogel Cancer Center shares MPN research updates she hopes to hear about at ASCO 2022.
Dr. Kristen Pettit:
Yeah, so the ASCO 2022 meeting will certainly be exciting for MPNs, I’m expecting the abstracts haven’t been selected yet as of the time we’re discussing this, so I’m not sure exactly what’s going to be discussed. But what I’m hoping to hear more about is the investigational JAK inhibitor momelotonib for patients with myelofibrosis, specifically those with anemia, I’m hoping to see more results about that.
I’m hoping to hear more about the up-front combination studies that are ongoing in myelofibrosis, so JAK inhibitors plus novel agents compared to JAK inhibitors alone as the first treatment option for patients with myelofibrosis. I’m hoping we get some interim results or updated results from some of those ongoing studies, and I’m hoping to hear more about some of the later line treatment options for patients with myelofibrosis as well.
There are a lot of exciting things going on out there, and we’ve gotten a couple of great updates over the last year, for example, at the ASH meeting in December, and I think we’ll get some more exciting updates at ASCO in May and June.